摘要
贫血是重症患者的常见问题,其病因是多因素的,主要包括各种原因导致的急性、非急性血液丢失;此外,炎症也会导致机体红细胞寿命缩短、红细胞生成减少。针对重症患者贫血的治疗,如各种止血药物(抗纤溶剂、去氨加压素、重组Ⅶa因子等)、红细胞生成素、血液替代品(全氟化碳、改良血红蛋白等)已被应用于临床或处于临床试验阶段,相关的血液保护策略的提出也为重症患者贫血提供了一个新的防治措施,是目前广大临床医师较为关注的问题。
Anemia of critical illness is common among intensive care unit patients. The causes are multifactorial and the major reason include the acute and non-acute blood loss;in addition, inflammation can lead to shortened life of the body＇s red blood cells and decreased red blood cells production. For the treatment of patients with anemia, various hemostatic drugs （ antifibrinolytie agent, 1-deamino-8-D-arginine vasopressin, recombinant factor Vlla） , erythropoietin and blood substitutes （perfluoroearbon, improved hemoglobin ）have been used in clinical or in clinical trials. Blood conservation strategies provides a new control measure for the patients, which is more concerned by the clinicians.
出处
《医学综述》
2013年第9期1630-1632,共3页
Medical Recapitulate
关键词
重症患者
贫血
血液保护
Critical patients
Anemia
Blood conservation
